Becton, Dickinson (BDX) has resumed US shipments of ChloraPrep after completing additional assessments and implementing final release testing, the company disclosed in a regulatory filing with the US Securities and Exchange Commission on Friday.
The company said it had voluntarily placed ChloraPrep and PurPrep on ship hold on May 6 while conducting additional final release testing tied to a warning letter from the US Food and Drug Administration for its El Paso manufacturing facility.
Becton, Dickinson said all additional testing completed to date has been acceptable and no patient safety signals have been identified.
Price: $148.91, Change: $+0.52, Percent Change: +0.35%